Exercise test was performed according to the incremental protocol using a treadmill system (Trackmaster TMX425C, www.selleckchem.com/products/Liproxstatin-1.html Newton, KS, USA). The running protocol consisted of 1-min workloads with participants beginning at a running speed of 8 km/h and increased by 2 km/h for each of subsequent workloads until volitional exhaustion.

Duration of the running protocol was identical at day 0 and day 14. Participants were asked to maintain their usual dietary intake and not to change their physical activity patterns during the study. Participants were instructed to report any side-effects of administration (e.g. headache, diarrhea, nausea, weight gain) through an open-ended questionnaire. Two-way analysis of variance (ANOVA) with repeated measures was used to establish if any significant differences existed between subjects’ responses over time of intervention (0 vs. 2 weeks). Where significant differences were found, the Tukey test was employed to identify the differences. P values of less than 0.05 were considered statistically significant. Effects-sizes in two way ANOVA with replication after two weeks of administration were assessed by Cohen statistics, with r > 0.24 indicated medium effect of mixed factors. The data were analyzed using the statistical

package SPSS 16.0, PC program (IBM SPSS Data Collection, New York, NY, USA). Results Changes PF-573228 concentration in fasting Selleck MK-0457 salivary and serum immunological profiles during the study are presented in Figure 1. Results indicated significant treatment × time interaction for salivary immunoglobulin A (P = 0.0002; r = 0.26), salivary immunoglobulin M (P = 0.02; r = 0.15), serum immunoglobulin A (P = 0.02; r = 0.16), NKC count (P = 0.01; r = 0.17), and NKC cytotoxic activity (P = 0.003; r = 0.25). Salivary immunoglobulin A increased significantly from before to after administration in nucleotides-administered participants (19.4 ± 3.5 vs. 25.6 ± 5.0 ml/100 mL; 95% CI 3.3–9.1, P < 0.0001;

r = 0.58). There were no significant differences in salivary and serum immunological outcomes before and after administration in the placebo group. After 14 days of administration, the nucleotides group had higher levels of serum immunoglobulin A than the placebo group (246.8 ± 22.5 vs. 201.4 ± 16.9 μmol/L, Enzalutamide manufacturer 95% confidence interval [CI] 32.3–58.5, P < 0.0001; r = 0.75), and higher levels of NKC cytotoxic activity (50.4 ± 14.5 vs. 29.3 ± 8.7 LU, 95% CI 13.2–29.0, P < 0.0001; r = 0.66). Salivary measures of immunity were significantly lower after the exercise trial in both nucleotides and placebo groups before as well as after the administration period (P < 0.05). Yet, administration of nucleotides for 14 days significantly diminished the drop of salivary immunoglobulins A (P =0.04; r = 0.13), salivary immunoglobulins M (P = 0.004; r = 0.18), and salivary lactoferrin after endurance test (P = 0.04, r = 0.08) (Figure 2).